Schrodinger, Inc. Common Stock (SDGR) Stock Price

SDGRStock

$22.60+11.28%52W

Market Cap$1.69B

P/E—

PEG Ratio—

Div yield—

Beta1.64

SDGR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)79.85%

Price vs S&P 500 (4W)-23.94%

VGM Score54.90

P/CF (Annual)121.64x

Book Value / Share (Quarterly)$4.40

P/TBV (Annual)4.70x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)12.23%

Cash Flow / Share (Quarterly)$-1.74

Price vs S&P 500 (YTD)14.47%

Gross Margin (TTM)56.87%

Net Profit Margin (TTM)-20.98%

EPS (TTM)$-0.74

10-Day Avg Trading Volume2.94M

EPS Excl Extra (TTM)$-0.74

Revenue Growth (5Y)18.81%

EPS (Annual)$-1.41

ROI (Annual)-28.37%

Gross Margin (Annual)55.74%

Net Profit Margin (5Y Avg)-53.39%

Cash / Share (Quarterly)$5.53

Revenue Growth QoQ (YoY)7.54%

ROA (Last FY)-14.22%

Revenue Growth TTM (YoY)8.88%

EBITD / Share (TTM)$-1.99

ROE (5Y Avg)-23.34%

Operating Margin (TTM)-59.24%

Cash Flow / Share (Annual)$0.17

P/B Ratio5.14x

P/B Ratio (Quarterly)3.69x

Net Income / Employee (Annual)$-121,500

EV / Revenue (TTM)5.42x

Net Interest Coverage (TTM)-63.83x

ROA (TTM)-8.19%

EPS Incl Extra (Annual)$-1.41

Current Ratio (Annual)2.75x

Quick Ratio (Quarterly)2.65x

3-Month Avg Trading Volume1.72M

52-Week Price Return11.28%

EV / Free Cash Flow (Annual)112.61x

Revenue / Employee (TTM)$304,700

Tangible BV / Share (Quarterly)$7.60

P/S Ratio (Annual)6.61x

Asset Turnover (Annual)0.35x

52-Week High$33.78

Operating Margin (5Y Avg)-81.97%

EPS Excl Extra (Annual)$-1.41

CapEx CAGR (5Y)-10.71%

Tangible BV CAGR (5Y)64.36%

26-Week Price Return89.76%

Quick Ratio (Annual)2.68x

13-Week Price Return47.52%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.71x

Enterprise Value$1.40B

Revenue / Share Growth (5Y)14.10%

Asset Turnover (TTM)0.39x

Book Value / Share Growth (5Y)-11.16%

Revenue / Employee (Annual)$301,000

Pretax Margin (Annual)-39.99%

Cash / Share (Annual)$5.37

3-Month Return Std Dev86.47%

Gross Margin (5Y Avg)57.54%

Net Income / Employee (TTM)$-63,900

ROE (Last FY)-28.37%

Net Interest Coverage (Annual)-3.42x

EPS Basic Excl Extra (Annual)$-1.41

Receivables Turnover (TTM)6.66x

EV / Free Cash Flow (TTM)46.68x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.74

Receivables Turnover (Annual)1.44x

ROI (TTM)-16.37%

P/S Ratio (TTM)6.53x

Pretax Margin (5Y Avg)-53.03%

Revenue / Share (Annual)$3.48

Tangible BV / Share (Annual)$7.60

Free OCF CAGR (5Y)-2.61%

Price vs S&P 500 (52W)-4.26%

Year-to-Date Return26.40%

5-Day Price Return-12.78%

EPS Normalized (Annual)$-1.41

ROA (5Y Avg)-13.36%

Net Profit Margin (Annual)-40.36%

Month-to-Date Return-27.21%

Cash Flow / Share (TTM)$0.68

EBITD / Share (Annual)$-2.19

Operating Margin (Annual)-65.23%

P/CF (TTM)69.74x

ROI (5Y Avg)-23.34%

EPS Basic Excl Extra (TTM)$-0.74

P/TBV (Quarterly)4.70x

P/B Ratio (Annual)3.62x

Pretax Margin (TTM)-20.05%

Book Value / Share (Annual)$4.94

Price vs S&P 500 (13W)44.83%

Beta1.64x

P/FCF (Annual)135.72x

Revenue / Share (TTM)$3.42

ROE (TTM)-16.37%

52-Week Low$10.95

vGradeD

gGradeC

mGradeB

vgmGradeC

SDGR Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	-$0.67	-$0.42	+37.87%(+$0.25)
Q1 2026	May 5, 2026	-$0.57	-$0.62	-8.95%(-$0.05)
Q4 2025	Feb 25, 2026	-$0.09	-$0.18	-100.22%(-$0.09)
Q3 2025	Nov 5, 2025	-$0.74	-$0.57	+22.97%(+$0.17)
Q2 2025	Aug 6, 2025	-$0.64	-$0.65	-1.56%(-$0.01)

SDGR Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.07

4.00

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
SDGRSchrodinger, Inc. Common Stock	D	C	B	6.5x	8.9%	56.9%	—	$22.60
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Schrodinger, Inc. Common Stock

Schrodinger is a software platform company that helps pharmaceutical, biotech, and materials science organizations accelerate molecular discovery and optimization. The company operates two segments: a Software segment that licenses its computational platform to enterprise customers (the primary revenue source), and a Drug Discovery segment that develops internal and collaborative preclinical and clinical programs. The United States represents the company's largest geographic market.

SDGR Next Earnings Report

Report dateNov 4, 2026

QuarterQ3 2026

Report timeAMC

Revenue estimate$47.63M

Also reporting on Nov 4, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

SDGR Insider Transactions

SellSep 17, 2026
AKINSANYA-AKIWUMI KAREN OLUFUNMILYO
Officer
Shares: 31,599Value: $927,970

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

NVAXNovavax IncBiological Products
ALVOAlvotech Ordinary SharesBiological Products
OLNOlin Corp.Chemicals
MESOMesoblast Limited American Depositary SharesBiological Products
VIRVir Biotechnology, Inc. Common StockBiological Products
NTLAIntellia Therapeutics, IncIn Vitro Diagnostics
MAZEMaze Therapeutics, Inc. Common StockBiological Products
IMCRImmunocore Holdings plc American Depositary SharesBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.0

Buy

Consensus rating

52-Week Range

Low$10.95

High$33.78